



CMS Waivers Provide Expanded Access to HFCWO Therapy

Waiver Extended
through
4/21/2021

In response to the COVID-19 pandemic, The Centers for Medicare and Medicaid Services (CMS) has provided greater flexibility for physicians to prescribe high frequency chest wall oscillation (HFCWO) therapy to Medicare beneficiaries.¹



What You Need to Prescribe SmartVest

The minimum documentation now required to prescribe SmartVest for Medicare beneficiaries is:

-1-

A valid SmartVest prescription



-2-

Documentation of a respiratory-related diagnosis



CMS Waiver Frequently Asked Questions

What happens to my patient's SmartVest after the waiver expires?

Patients who receive a SmartVest under CMS waiver exemption will have lifetime access to the therapy following waiver expiration, without new or additional cost or reimbursement requirements.

Do CMS waivers apply towards commercial or managed Medicare plans?

The current waiver applies to traditional Medicare beneficiaries and does not extend to commercial or managed Medicare plans.

What respiratory-related diagnoses qualify for reimbursement under the CMS waiver? In addition to bronchiectasis and neuromuscular conditions, the CMS waiver provides HFCWO therapy coverage for any respiratory-related diagnosis determined by a clinician, including chronic obstructive pulmonary disease (COPD).

We're in this Together.

Electromed is here to support your care team and help you provide patients with the best care possible, when and where they need it.

smartvest[®]
AIRWAY CLEARANCE SYSTEM

Questions?

Contact SmartVest at **800.462.1045**
or visit **smartvest.com**

1. Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency, 66 Fed. Reg. 19230, 19266 (April 6, 2020).